Sequencing Technology Comparison for Detection of HIV-1 **Mutations in the Protease and Reverse Transcriptase Regions**

Elian Rakhmanaliev¹; Pramila Ariyaratne¹; Alex Yeo¹; Charlie Lee¹; Pornpimon Nimitsuntiwong²; Chortip Wathtphan²; Zhang Rui¹; Ekawat Passomsub²; Wasun Chantratita² and Gerd Michel¹

INTRODUCTION

Resistance of HIV to antiretroviral drugs is the most common cause for therapeutic failure in people infected with Human Immunodeficiency Virus (HIV) [1]. Objective of this study was to compare two sequencing-based HIV-1 drug resistance monitoring systems: an CLIP-based system (TruGene HIV-1 Genotyping Kit) and a novel Next Generation Sequencing (NGS)-based test (Sentosa SQ HIV-1 Genotyping Assay).

MATERIAL & METHODS

We used an automated NGS-based integrated workflow, comprised of 1) a robotic liquid handling system for nucleic acid extraction and NGS library preparation (Sentosa[®] SX101); 2) Ion Torrent instruments for deep sequencing [2]; 3) kits for RNA extraction, HIV NGS library preparation and deep sequencing, and 4) data analysis and reporting software (Fig. 1). Reporting includes 86 Drug Resistance Mutations (DRMs) across the Reverse Transcriptase (RT), Protease (PR) and Integrase genes (Fig. 2 and 3). 111 prospective EDTA plasma clinical samples from patents infected with HIV-1 were tested for this study.



Figure 1. Vela's NGS workflow for the HIV Genotyping Assay.



¹Vela Research Pte. Ltd., Singapore; ²Department of Pathology, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand



All samples were tested on both systems. 97.3% (108/111) samples were subtyped as CRF01_AE. In total, 647 DRMs were detected (435 in the RT gene, 199 in the PR gene and 13 in the Integrase gene). The Sentosa SQ HIV Genotyping Assay detected 100% (199/199) of all DRMs in the PR gene and more that 98% DRMs (427/435) in the RT gene. The Integrase gene was not included into the comparison study because it is not covered by the TruGene test. In total, 130 DRMs were detected by the Sentosa SQ HIV Genotyping Assay, that were not found by TruGene and 8 DRMs were missed by the Sentosa HIV Genotyping Assay (but detected by TruGene). Mutation detection rates for both assays are presented in **Table 1**.

Table 1. Mutation detection rates for the TruGene HIV-1 Genotyping and Sentosa[®] SQ HIV Genotyping Assays.

HIV Gene	Test	Number of Mutations	Mutations Detected	Detection rate	95% Confidence Interval
Protease	Sentosa [®] SQ HIV Genotyping Assay	199	199	100.00%	98.11 – 100.00%
FIDIEASE	TruGene HIV-1 Genotyping Kit	199	180	90.45%	85.57 – 93.80%
Reverse	Sentosa [®] SQ HIV Genotyping Assay	435	427	98.16%	96.41 – 99.07%
Transcriptase	TruGene HIV-1 Genotyping Kit	435	324	74.48%	70.18 – 78.35%
Overall	Sentosa [®] SQ HIV Genotyping Assay	634	626	98.74%	97.53 – 99.36%
	TruGene HIV-1 Genotyping Kit	634	504	79.50%	79.02 – 79.62%

All HIV strains were carrying one or multiple DRMs in 61, 16 and 9 AA positions of the RT, PR and Integrase genes respectively. The most prevalent DRMs in the RT and PR genes are listed in **Table 2**.

Table 2. The most prevalent mutations in the tested population.

Gene	Mutation	Percentage	Resistance to / Effect
	M184V	48,7% (54/111)	3TC, FTC (NRTI), ddl
Dovoroo	K103N	29.7% (33/111)	NVP and EFV (NNRTI)
Reverse Transcriptase	Y181C	27,9% (31/111)	NVP, ETR, RPV, EFV (NNRTI)
	G190A	18.9% (21/111)	NVP, EFV (NNRTI)
	D67N	18.9% (21/111)	AZT, d4T (NRTI), ddl
	M36I	91.9% (102/111)	Increases the replication fitness of viruses with PI-resistance mutations
Protease	K20R	21.6% (24/111)	Increases the replication fitness of viruses with PI-resistance mutations
	L10I	20.7% (23/111)	Either reduce PI susceptibility or increase the replication of viruses containing PI-resistance mutations

RESULTS

ale of Birth: ge: ender: alment Do Hospital: tysiclan(s): say Name: Pathologists signature Pathologists signature B Subtype detected: B. Methodology: argeted next-generation sequencing was performed on this CR. The amplicons wore enzymatically fragmented and liga enterpretation: subtype detected: B. Methodology: argeted next-generation argeted next-generation References Used: Uman immunodeficiency virus type 1 (HXB2) Assay Information: be Sontosa [®] SO HIV Genotyping Assay is a next generation iagnosed with HIV infection from human plasma or sorum. T irus Total Nucleic Acid Plus II Kit in conjunction with the Sori Assay So HIV Genotyping Assay is a next generation iagnosed with HIV infection from human plasma or sorum. T irus Total Nucleic Acid Plus II Kit in conjunction with the Sori Assay Name: Sonte of Birth: Patient Information: Name of Patient: Patient Information: Name of Patient: Patient ID: Name/ID of Hospital: Physician(s): Assay Name: Sentosa.SQLHIV.Genotyping Assay is a next generation gender: Patient History: Assay Name: Sentosa.SQLHIV.Genotyping assay is a next generation assay Name: Sentosa.SQLHIV.Genotyping Assay is a next generation Sentosa [®] SQ HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SQL HIV Genotyping Assay is a next generation Sentosa [®] SQ HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SQL HIV Genotyping Assay is a next generation Sentosa [®] SQL HIV Genotyping Assay is a next generation Sentosa [®] SQL HIV Genotyping Assay is a next generation Sentosa [®] SQL HIV Gen	Pathology Repore Patient Information:	
atient ID: ameniD of Hospital: hysiolan(s): sawy Name: Sentosa_SQ_HIV_Genotyping_F atient History: Pathologist's signature Pathologist's signature Pathologist's signature Name printer Sentotypes: To Gene Subtype B nterpretation: subtype detected: B. Methodology: argoled next-generation: subtype detected: B. Methodology: argoled next-generation: Base-calling) on the raw sequencing data generated by Sonto generation: Base-calling) on the raw sequencing data generated by Sonto generation: Based Methodology: Assay Information: Cene List: Belective: Disclaimer: Name //D of Hospital: Physician(s): Assay Name: Date of Bith: Age: Gender: Patient ID: Name//D of Hospital: Physician(s): Assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay is a next generation assay Name: Sentosa [®] SO HIV Genotyping Assay	Name of Patient: Date of Birth: Age:	
seay Name: Sentosa_SQ_HIV_Genotyping_J attent History: Pathologist's signature Name printed Senotypes: To Gene Subype Sectorypes: To Gene Subype Sectorypes: To Gene Subype B Interpretation: subype delected: B. Methodology: argeled next-generation sequencing was performed on this CR. The amplicors were rerymatically fragmented and liga sentosa® SQI sequencing instrument. Subequently, Sa ase-calling) on the raw sequencing data generated by Sento seporter Sover for secondary analysis and report generation References Used: Uman immunodeficiency virus type 1 (HXB2) Assay Information: Inse Sontosa® SQI HV Genotyping Assay is a next generation agnosed with HIV infection from human plasma or serum. T Times Tota Nuccle Acid Plus II Kit in conjunction with the Sento Sentosa® SQI HV Genotyping Assay is a next generation diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labo lel is a trademark of Vela Holding Pte Ltd. Sentosa® is a red recision pursuant to the requirements of CLIA' 88. This labo lel is a trademark of Vela Holding Pte Ltd. Sentosa® is a red red the European Union. Quality Control Report Patient Information: Name of Patient: Date of Birthic: Date of Birthic: Da	Gender: Patient ID: Name/ID of Hospital: Physician(s):	
Pathologist's signature Name printer Pathologist's signature Name printer Secotypes: Subtype Note Gene Subtype detected: B. Subtype Arethodology: B argued next-generation: subsequenting was performed on this CR. The ampleorations were enzymatically fragmented and liggenrotea® ¹⁵ SO301 sequencing instrument. Subsequently, Stasso-calling) on the raw sequencing data generated by Service porter Server for secondary analysis and report generation agnosed with HW infection from human plasma or serum. Trives Total Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus II Kt in conjunction Plus Nucleic Acid Plus II Kt in conjunction analysis of Protease (codons 1-99), NRT orformed. Clause Technic Nucleic Acid Plus II Kt in conjunction Plus Nucleic Acid Plus II Kt in conjunction with the Serie Scale Nucleic Acid Plus Holding Plus Lt. Seniosa® Scale Nucleic Acid Plus II Kt in conjunction Plus Nucleic Acid Plus II Kt in conjunction Plus Nucleic Acid Plus II Kt in conjunction and the European Union. Clause Technic Nucleic Acid Plus II Kt in conjunction Scale Scale Nucleic Acid Plus II Kt in conjunction Scale Scale Nucleic Acid Plus II Kt i	Assay Name: Sentosa. Run ID:	SQ_HIV_Genotyping_A
Pathologist's signature Name printer Sciencitypes: Subtype Ac. Gene Subtype Sciencitypes: B Action of the problem of the science of the scince of the science of the science of the scie	-	
No. Cene Subtype B B Interpretation: subtype detected: B. Antername Ageneration sequencing was performed on this CR. The amplicons were enzymatically fragmented and liga erroraca® S0301 sequencing instrument. Subsequently, S. ase-calling) on the raw sequencing data generated by Sento exporter Sever for secondary analysis and report generation References Used: Iuman immunodeficioncy virus type 1 (HXB2) Assay Information: hs Sontosa® SO HIV Gonotyping Assay is a next generation ingnosed with HIV infection from human plasma or serum. T irus Total Nucleic Acid Plus II Kt in conjunction with the Sento- Cene List: Belective mutation analysis of Protease (codons 1-99), NRI eroistin, Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labo ele is a trademark of Vela Holding Pte Ltd. Sentosa® is a red difficult formation: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name of Patient: Date of Birth: Age: Sentosa® SO HIV Genotyping Assay is a next generation patients diagnosed with HIV infection from human plasma osentosa® SX Virus Total Nucleic Acid Plus II Kit in conjunction Run Quality Controls: Quality Controls: Pastient History: Assay Name: Sentosa.SQ.HIV.Genotyping Assay is a next generation osentosa® SX Virus Total Nucleic Acid Plus II Kit in conjunction Run Quality Controls: Positive Control Mamodia Bases (%) System Control PASS PASS Pass Invalid Reads (%) - Invalid Bases (%) System Control - No Template Control PASS Extraction Cantrol - SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Va	Pathologist's signature	Name printed
B nterpretation: subtype detected: B. Aethodology: argebat next-generation sequencing instrument. Subsequently, Sase-calling) on the raw sequencing data generated by Service server for secondary analysis and report generation aporter Server for secondary analysis and report generation agnosed with HW infection from human plasma or serum. Trus Total Nucleic Acid Plus II Kit in conjunction with the Serial Sagnosed with HW infection from human plasma or serum. Trus Total Nucleic Acid Plus II Kit in conjunction with the Serial Sagnosed with HW infection from human plasma or reformed. Disclaimer: Disclaimer: his test was developed and its performance determined by diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labo elia is a trademark of Vela Holding Ple Ltd. Sentosa® is a red the European Union. Quality Control Report Patient Information: Name of Patient: Date of Birth: Age: Assay Information: The Sentosa® So HW Genotyping Assay is a next generation generatic patient Bistory: Acsay Information: Patient History: Assay Name: Sentosa® SO HW Genotyping Assay is a next generatic patients diagnosed with HW infection from human plasma o serum. The Sentosa® SO HW Genotyping Assay is a next generatic patients diagnosed with HW infection from human plasma o serum. The Sentosa® SO HW Genotyping Assay is a next gener	Genotypes: No. Gene	Subtype
subtype detected: B. Acthodology: argeted next-generation sequencing was performed on this GR. The amplicons were erzymatically fragmenited and liga reforsas [®] SQOI sequencing instrument. Subsequently, Sase-calling) on the raw sequencing data generated by <i>Serict</i> exporter Server for secondary analysis and report generation agenosed with HIV infection from human plasma or serum. T irus Total Nucleic Acid Plus II KII in conjunction with the <i>Seri</i> Cene List: elective mutation analysis of Protease (codons 1-99), NRT erformed. Disclaimer: his test was developed and its performance determined by diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This tabo ela is a trademark of Vola Holding Ple Ltd. <i>Sentosa</i> [®] is a re nd the European Union.	1	
Actional Control Sequencing was performed on this CR. The amplicons were enzymatically fragmented and liga tentosa® SQ301 sequencing instrument. Subsequently, Sease-calling) on the raw sequencing data generated by Sento eporter Server for secondary analysis and report generation References Used: Umman immunodoficiency virus type 1 (HXB2) Assay Information: he Sentosa® SQ HIV Genotyping Assay is a next generation agnosed with HIV infection from human plasma or serum. Tirus Total Nucleic Acid Plus II Kit in conjunction with the Sent Gene List: elective mutation analysis of Protease (codons 1-99), NRI enformed. Disclaimer: his best was developed and its performance determined by diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labole is a trademark of Vela Holding Plue Ltd. Sentosa® is a red of the European Union. Quality Control Report Patient Information: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name of Patient: Date Set Mis Control Control </td <td>nterpretation: subtype detected: B.</td> <td></td>	nterpretation: subtype detected: B.	
Assay Information: he Sentosa [®] SQ HIV Genotyping Assay is a next generation liagnosed with HIV infection from human plasma or serum. T irus Total Nucleic Acid Plus II Kit in conjunction with the Sent Sene List: elective mutation analysis of Protease (codons 1-99), NRT procession, pursuant to the requirements of CLIA' 88. This labo bela is a trademark of Vela Holding Ple Ltd. Sentosa [®] is a re- nd the European Union. Quality Control Report Patient Information: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name of Patient: Date of Birth: Age: Gender: Patient History: Assay Name: Sentosa.SQ.HIV.Genotyping. Patient History: Assay Name: Sentosa.SQ.HIV.Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa [®] SQ HIV Genotyping Assay is a next generatic patient Bistory: Assay Name: Sentosa SQ HIV Genotyping Assay is a next generatic patient Bistory: Assay Name: Sentosa SQ Nirus Total Nucleic Acid Plus II Kit in conjunctio Run Throughput (bp) PASS Invalid Reads / Bases Invalid Reads / Bases Invalid Reads (%) System Control SC Mutation #1 (Variant Frequency) SC Mutation #1 (Variant Frequency) SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) PASS Protease / RT Assembly - Control Amplicon Median Coverage	PCR. The amplicons were enzymaticall Sentosa [®] SQ301 sequencing instrume base-calling) on the raw sequencing da Reporter Server for secondary analysis References Used:	ly fragmented and ligate ent. Subsequently, <i>Se</i> ta generated by <i>Sentos</i> and report generation.
Gene List: elective mutation analysis of Protease (codons 1-99), NRT erformed. Disclaimer: his test was developed and its performance determined by diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labo ela is a trademark of Vela Holding Pte Ltd. Sentosal® is a re nd the European Union. Quality Control Report Patient Information: Name of Patient: Date of Birth: Age: Gender: Patient D1: Name of Patient: Date of Birth: Age: Gender: Patient D1: Name/D of Hospital: Physician(s): Assay Name: Sesay Name: Sentosa® SQ HIV Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa® SX Virus Total Nucleic Acid Plus II Kti in conjunctio Run Ducality Controls: QC Metric QC 4 Navial Reads (%a) PASS Invalid Reads (Bases PASS Variant Frequency) SC Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) SC Mutation #3	Assay Information: The Sentosa [®] SQ HIV Genotyping Assa liagnosed with HIV infection from huma	ay is a next generation s an plasma or serum. Th
erformed. Disclaimer: his test was developed and its performance determined by diministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA' 88. This labolela is a trademark of Vela Holding Pte Ltd. Sentosa ^(B) is a re nd the European Union.	Gene List:	
his lest was developed and its performance determined by dministration. Since FDA is not required for clinical use of recision, pursuant to the requirements of CLIA'88. This labou ela is a trademark of Vela Holding Pte Ltd. Sentosa® is a re- dn the European Union.	performed.	e (codons 1-99), NRTI
Patient Information: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name/ID of Hospital: Physician(s): Assay Name: Sentosa_SQ_HIV_Genotyping_Patient History: Assay Name: Sentosa_SQ_HIV_Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa [®] SX Virus Total Nucleic Acid Plus II Kit in conjunctio Run Quality Controls: QC Metric QC Metric QC 1 Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS Invalid Reads (%) PASS System Control PASS - Invalid Bases (%) System Control System Control PASS - SC Mutation #1 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #1 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - Protease / RT Assembly Protease / RT Assembly - Protease / RT Assembly Pass - Integrase Assee mbly	his test was developed and its perfor administration. Since FDA is not requi recision, pursuant to the requirements	red for clinical use of t of CLIA' 88. This labor
Patient Information: Name of Patient: Date of Birth: Age: Gender: Patient ID: Name/ID of Hospital: Physician(s): Assay Name: Sentosa_SQ_HIV_Genotyping_Patient History: Assay Name: Sentosa_SQ_HIV_Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa [®] SX Virus Total Nucleic Acid Plus II Kit in conjunctio Run Quality Controls: QC Metric QC Metric QC 1 Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS Invalid Reads (%) PASS System Control PASS - Invalid Bases (%) System Control System Control PASS - SC Mutation #1 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #1 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - Protease / RT Assembly Protease / RT Assembly - Protease / RT Assembly Pass - Integrase Assee mbly	Quality Control	Report
Gender: Patient ID: Name/ID of Hospital: Physician(s): Assay Name: Sentosa_SQ_HIV_Genotyping_Patient History: Assay Name: Sentosa_SQ_HIV_Genotyping_Assay is a next generatic patients diagnosed with HIV infection from human plasma o <i>Sentosa®</i> SX Virus Total Nucleic Acid Plus II Kit in conjunction Run Quality Controls: QC Metric QC Settic Acid Plus II Kit in conjunction Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS Invalid Reads / Bases PASS Invalid Reads (%) PASS Invalid Bases (%) System Control System Control PASS - No Template Control PASS S C Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS Straction Control PASS Integrase Assembly Protease / RT Assembly - Protease / RT Assembly Protease / RT Assembly - Control Amplicon Median Coverage SAM Tools MIRA Mira 3.4.1 MMAP SAM Tools 0.1.19-444286 Sentosa® SQ Reporte	Patient Information: Name of Patient: Date of Birth:	
Patient History: Assay Information: The Sentosa® SQ HIV Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa® SX Virus Total Nucleic Acid Plus II Kit in conjunctio Run Quality Controls: QC Metric QC Metric QC S Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS - Invalid Bases (%) PASS System Control PASS - Positive Control (Assembly Quality) PASS - No Template Control PASS - SC Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS - SC Mutation #1 (bp) PASS Sample Quality Controls: PASS QC Metric QC S Sample Throughput (bp) PASS - Integrase Assembly Pass - Protease / RT Assembly Pass - Control Amplicon Median Coverage SAM Tools 0.1.19-444286 Sata Tools SAM Tools 0.1.19-444286	Gender: Patient ID: Name/ID of Hospital: Physician(s):	a_SQ_HIV_Genotyping 4
The Sentosa® SQ HIV Genotyping Assay is a next generatic patients diagnosed with HIV infection from human plasma o Sentosa® SX Virus Total Nucleic Acid Plus II Kit in conjunctio Run Quality Controls: QC Metric QC S Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS Invalid Reads / Bases PASS Invalid Reads (%) PASS Invalid Bases (%) System Control System Control PASS - Positive Control (Assembly Quality) PASS - No Template Control SC Mutation #1 (Variant Frequency) - SC Mutation #2 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS - Integrase Assembly PASS - Integrase Assembly PASS - Integrase Assembly PASS - Integrase Assembly Pass - Protease / RT Assembly Pass - Integrase Assembly Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter <th>Patient History:</th> <th></th>	Patient History:	
Run Throughput (bp) PASS Loading (%) PASS Key Signal PASS Invalid Reads / Bases PASS - Invalid Reads (%) - - Invalid Bases (%) PASS System Control PASS - No Template Control PASS - No Template Control PASS - SC Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS - SC Mutation #3 (Variant Frequency) PASS - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS Sample Quality Controls: QC S Sample Throughput (bp) PASS - Integrase Assembly Protease / RT Assembly - Protease / RT Assembly Protease - Control Amplicon Median Coverage Mira 3.4.1 MIRA Mira 3.4.1 TMAP SAM Tools 0.1.19-444280 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	The Sentosa [®] SQ HIV Genotyping As patients diagnosed with HIV infection Sentosa [®] SX Virus Total Nucleic Acid Run Quality Controls:	from human plasma or Plus II Kit in conjunctior
Key Signal PASS Invalid Reads / Bases PASS Invalid Reads (%) PASS - Invalid Bases (%) PASS System Control PASS - Invalid Bases (%) PASS System Control PASS - Positive Control (Assembly Quality) PASS - No Template Control PASS - SC Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) PASS - SC Mutation #3 (Variant Frequency) PASS Sample Quality Controls: QC 9 Sample Throughput (bp) PASS - Integrase Assembly Pass - Integrase Assembly Protease / RT Assembly - Control Amplicon Median Coverage Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	Run Throughput (bp)	PASSI PASSI
- Invalid Bases (%) System Control Assembly Quality - No Template Control - SC Mutation #1 (Variant Frequency) - SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) - SC Mutation #3 (Variant Frequency) Sample Quality Controls: QC Metric QC S Sample Throughput (bp) PASS Extraction Control PASS - Integrase Assembly - Protease / RT Assembly - Control Amplicon Median Coverage Databases and Tools Version: Reference Veladx Reference - hg19. MiRA Mira 3.4.1 TMAP TMAP 4.0.5 SAM Tools SAM Tools 0.1.19-444280 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	Key Signal Invalid Reads / Bases - Invalid Reads (%)	PASS
- No Template Control - SC Mutation #1 (Variant Frequency) - SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) Sample Quality Controls: QC Metric QC S Sample Throughput (bp) PASS Extraction Control PASS - Integrase Assembly - Protease / RT Assembly - Control Amplicon Median Coverage Databases and Tools Version: Reference Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP Mira 3.4.1 TMAP Mira 3.4.1 TMAP Mira 3.4.1 TMAP Mira 3.4.1 TMAP SAM Tools SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	 Invalid Bases (%) System Control Positive Control (Assembly Quality) 	PASS
- SC Mutation #1 (Variant Frequency) - SC Mutation #2 (Variant Frequency) - SC Mutation #3 (Variant Frequency) Sample Quality Controls: QC Metric QC S Sample Throughput (bp) PASS Extraction Control PASS - Integrase Assembly - Protease / RT Assembly - Control Amplicon Median Coverage Databases and Tools Version: Reference Veladx Reference - hg19. MiRA Mira 3.4.1 TMAP Veladx Reference - hg19. Mira 3.4.1 TMAP Mira 3.4.1 TMAP SAM Tools SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Repo	- No Template Control	
QC Metric QC S Sample Throughput (bp) PASS Extraction Control PASS - Integrase Assembly Pass - Protease / RT Assembly Protease / RT Assembly - Control Amplicon Median Coverage Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP TMAP 4.0.5 SAM Tools SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	 No template Control SC Mutation #1 (Variant Frequency) SC Mutation #2 (Variant Frequency) SC Mutation #3 (Variant Frequency) 	
QC Metric QC S Sample Throughput (bp) PASS Extraction Control PASS - Integrase Assembly Pass - Protease / RT Assembly Protease / RT Assembly - Control Amplicon Median Coverage Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP TMAP 4.0.5 SAM Tools SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter		
Extraction Control PASS - Integrase Assembly Protease / RT Assembly - Control Amplicon Median Coverage Control Amplicon Median Coverage Databases and Tools Version: Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP TMAP 4.0.5 SAM Tools SAM Tools 0.1.19-444286 Sentosa® SQ Reporter Veladx Sentosa SQ Reporter	QC Metric Sample Throughput (bp)	QC S PASS
- Control Amplicon Median Coverage Databases and Tools Version: Reference Veladx Reference - hg19. MIRA Mira 3.4.1 TMAP TMAP 4.0.5 SAM Tools SAM Tools 0.1.19-444280 Sentosa [®] SQ Reporter Veladx Sentosa SQ Repo	Extraction Control - Integrase Assembly	PASS
ReferenceVeladx Reference - hg19_MIRAMira 3.4.1TMAPTMAP 4.0.5SAM ToolsSAM Tools 0.1.19-444280Sentosa® SQ ReporterVeladx Sentosa SQ Reporter	- Protease / RT Assembly - Control Amplicon Median Coverage	
ReferenceVeladx Reference - hg19_MIRAMira 3.4.1TMAPTMAP 4.0.5SAM ToolsSAM Tools 0.1.19-444280Sentosa® SQ ReporterVeladx Sentosa SQ Reporter		
SAM Tools SAM Tools 0.1.19-444280 Sentosa [®] SQ Reporter Veladx Sentosa SQ Reporter	ReferenceVelMIRAMirTMAPTM	ladx Reference - hg19_l 'a 3.4.1
Figure 4. An exa	SAM Tools SA	M Tools 0.1.19-44428c
rigure 4. An exa		A 10
	rigure 4. A	чп еха
	Detection	and r
Detection and r		
Detection and reasons and reasons and reasons and each	_	_
regimen and car	drugs. Hig	h sen
	0 0	around
regimen and car	Ŭ Ŭ	
regimen and car drugs. High sen short turnaround	short turna	or dete
regimen and car drugs. High sen	short turna	or dete

1) Vella S., Palmisano L. Clin Infect Dis. 2005 41(4): S239-S246 2) Loman N. et al. Nat. Biotechnol. 2012 May 30(5):434-9.

RUO: For research use only. Not for use in diagnostic procedures.





uple of a QC Report generated by Sentosa[®] SQ Reporter.

CONCLUSIONS

porting of DRMs is critical for optimal selection of HAART prevent or minimize the development of resistance to antiviral itivity (up to 5% mutation frequency) and the comparatively ime of 2.5 days make this NGS-based workflow a promising ing relevant mutations in HIV-1.

REFERENCES

www.veladx.com